Abstract
A consecutive series of 36 children with bleeding from oesophageal varices secondary to extrahepatic portal hypertension was successfully treated by endoscopic injection sclerotherapy and followed up over a mean period of 8.7 years after variceal obliteration. There were no deaths from portal hypertension or its treatment and morbidity related to oesophageal sclerotherapy was minimal. Endoscopic injection sclerotherapy alone proved safe and effective in controlling variceal bleeding from portal hypertension in over 80% of the children. Recurrent variceal bleeding developed in 10 (31%) patients but half of these were effectively treated by further sclerotherapy. Gastric variceal bleeding unresponsive to sclerotherapy necessitated successful portosystemic shunt surgery in four (13%) patients. Two children required splenectomy for painful splenomegaly. In most children injection sclerotherapy is the best treatment for the primary management of bleeding oesophageal varices, reserving portosystemic shunting or other surgical procedures for those with bleeding from gastrointestinal varices.

Bleeding from oesophageal varices is the commonest cause of serious gastrointestinal haemorrhage in children and is associated with a death rate of 5-9% in those with portal vein obstruction and a considerably greater morbidity and mortality in children with cirrhosis.† Opinions on the primary management of this condition have long been divided between those who advocate portosystemic shunting‡ and those who favour endoscopic injection sclerotherapy.‡ The published results of endoscopic injection sclerotherapy in large numbers of children with oesophageal varices have recently encouraged the widespread acceptance of the technique§ but there is little information on the longterm results. While this may be less important for those with primary intrahepatic disease, in whom prognosis is largely determined by underlying liver pathology, such data are essential for those with portal vein obstruction in whom variceal bleeding is the main threat to life.

We therefore reviewed a cohort of children who had previously had injection sclerotherapy for bleeding oesophageal varices secondary to extrahepatic portal hypertension.

Patients and Methods
In 1988, we reported the initial results of endoscopic injection sclerotherapy for bleeding oesophageal varices in a consecutive series of 36 children with portal vein obstruction.† Mean age at onset of variceal bleeding was 5 years and 10 patients had previously had a variety of unsuccessful surgical procedures for portal hypertension. Oesophageal varices were successfully obliterated by injection sclerotherapy in all cases without death and within a mean period of less than one year.

Subsequent surveillance endoscopies were performed at six month to two yearly intervals. Small asymptomatic lower oesophageal and contiguous fundal varices were injected with small volumes of sclerosant. Patients who developed gastrointestinal bleeding from portal hypertension despite obliteration of oesophageal varices had arteriopography to define portal venous anatomy.

Results
Four patients were lost to follow up after successful treatment of oesophageal varices and have been excluded from further analysis. The remaining 32 patients (21 males, 11 females) have a current mean age of 17.2 (6.8-26.7) years and have been under review for a mean period of 8.7 (3.7-12.8) years since variceal obliteration. (Figure)

MORTALITY
One 8 year old boy died from a myocardial infarction associated with an anomalous left coronary artery, six years after successful treatment of his varices.

Diagram
RECURRENT BLEEDING

Recurrent gastrointestinal bleeding occurred in 12 patients but was a result of peptic ulceration in two who were successfully treated with drugs. Five children, including one who defaulted from follow up, developed melena or haematemesis, or both due to recurrent oesophagogastric varices, which were controlled by further sclerotherapy. Four patients required portosystemic shunting for bleeding gastric varices unresponsive to injection sclerotherapy, one of whom had previously bled from jejunal ulcers associated with a neonatal duodenoejunostomy for duodenal atresia. One 11 year old boy with a history of a single minor recurrent bleeding episode has an erythematous patch of mucosa in the duodenum associated with duodenal varices; this lesion has been injected once and he remains under observation. Four of these 12 children had multiple sites of gastrointestinal bleeding; the boy with jejunal ulceration and gastric varices and three who required a variety of local treatments for bleeding anorectal varices.

LONGTERM SCLEROTHERAPY COMPLICATIONS

Oesophageal strictures associated with the initial sclerotherapy course did not recur. One child developed mild dysphagia after injections at surveillance endoscopies and this responded to a single oesophageal dilatation and two other patients have mild asymptomatic reflux oesophagitis detected at endoscopy.

SURGICAL PROCEDURES

Sixteen patients were studied by angiography, 14 after completion of sclerotherapy, of whom nine were found to have isolated portal vein occlusion whereas five had additional splenic and superior mesenteric venous thrombosis. Two children had angiography before sclerotherapy, one of whom had thrombosis/collateralisation of both the splenic and main portal veins. Six patients required surgery for complications of portal hypertension (Table). Mesocaval shunts were constructed using autologous internal jugular vein and all patients are currently well with patent shunts.

GENERAL PROGRESS

Four patients had a history of inguinal herniotomy (bilateral in two), which may reflect an increased intra-abdominal pressure from splenomegaly. Of those who have not had portosystemic shunting or splenectomy, half have persistent thrombocytopenia (<100×10^9/l) and comparative leucopenia pointing to hypersplenism. Data on height and weight were available for 26 children and were unremarkable except that 9 of 19 boys had heights above the 90th centile.

Of 15 patients over 18 years, 12 are in full time employment and two have had children.

Discussion

The efficacy of endoscopic injection sclerotherapy in controlling bleeding from oesophageal varices is well established. The technique is widely used in treating variceal haemorrhage in patients with cirrhosis, although its role in the management of patients with extrahepatic portal hypertension remains controversial. In children, there is scant information on the longterm morbidity of oesophageal sclerotherapy and on the subsequent incidence of bleeding from gastrointestinal or recurrent oesophageal varices. Children with portal vein occlusion, in whom liver function is essentially normal, best exemplify the longterm problems associated with portal hypertension. This study has reviewed a cohort of such patients who have been followed up into adulthood over a mean period of nine years.

There were no deaths from portal hypertension or its treatment and minimal morbidity related to oesophageal sclerotherapy. We found no angiographic evidence to support the suggestion that splenic or mesenteric venous occlusion occurs in a significant proportion of patients with portal vein obstruction as a result of sclerotherapy. Although 5 of 14 (36%) children showed evidence of extensive mesenteric venous occlusion, angiography was only carried out in our more complicated patients and other authors have identified concomitant splenic or superior mesenteric venous occlusion, or both, in more than 20% of children with extrahepatic portal hypertension when first investigated. It is noteworthy that Rice et al, using detailed duplex Doppler sonography in adults with cirrhosis and oesophageal varices, were unable to show any evidence of splenic vein thrombus after sclerotherapy. The potential longterm risk of neoplasia from childhood sclerotherapy remains a concern but despite the global application of this technique in patients with portal hypertension, there are only a few isolated reports of this association. Moreover, recognised risk factors for oesophageal cancer have coexisted in these adults and a recent systematic study using brush cytology failed to support an association with neoplasia. Nevertheless, both the longterm efficacy and morbidity of sclerotherapy must remain under review.

Recurrent variceal bleeding developed in 10 (31%) patients but half of these were effectively controlled by further sclerotherapy. Gastric variceal bleeding not amenable to sclerotherapy necessitated portosystemic shunt surgery in four (13%) patients. In recent years we have preferred the mesojugular-caval shunt, which confers the best chance of longterm patency and the lowest incidence of rebleeding. Bleeding from anorectal varices was successfully treated by...
Long-term outcome after injection sclerotherapy for oesophageal varices in children with extrahepatic portal hypertension

... in children with portal vein occlusion. These results support our previous conclusion that in most children injection sclerotherapy is the best treatment for the primary management of bleeding oesophageal varices. Nevertheless, almost 20% of patients have required surgery, either splenectomy for symptomatic splenomegaly or portosystemic shunting for gastrointestinal variceal bleeding. When possible, shunt surgery is effective in such situations and the technical results of portosystemic shunting in extrahepatic portal hypertension have continued to improve. The longterm management of children with portal vein occlusion demands the use of a variety of complementary techniques each of which may be limited by applicability, efficacy, and longterm complications. Our current policy is to control oesophageal variceal bleeding by injection sclerotherapy. We reserve portosystemic shunting for those with bleeding from gastrointestinal varices and devascularisation, transection or direct suture for the same problem in the rare child where shunting is not possible.